IP Library Granted Patent US 10,626,138
Granted Patent B2
US 10,626,138 · App. 14/910,203 · Granted Apr 21, 2020

Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides

Inventors: Floyd E. Romesberg (La Jolla, CA); Denis A. Malyshev (Solana Beach, CA); Lingjun Li (San Diego, CA); Thomas Lavergne (Le Versoud, FR); Zhengtao Li (Pudong new district, CN)
Assignees: THE SCRIPPS RESEARCH INSTITUTE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT OF HEALTH AND HUMAN SERVICES (DHHS); U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)
C07H19/24C07H19/00C07H21/00C12P19/34C12Q1/6832
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,626,138
App. No.
14/910,203
Granted
Apr 21, 2020
Kind
B2
Abstract

Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.

Claims (29)

1. A compound of formula:

wherein R 2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, methoxy, methanethiol, methaneseleno, halogen, cyano, and azido; and

the wavy line indicates a bond to a ribosyl, 2′-deoxyribosyl, or 2′, 3′-dideoxyribosyl moiety, wherein the 5′-hydroxy group of the ribosyl, 2′-deoxyribosyl, or 2′, 3′-dideoxyribosyl moiety is in free form, or is optionally bonded to a monophosphate, a diphosphate, or a triphosphate group.

2. The compound of claim 1 , wherein the wavy line indicates a bond to a ribosyl or 2′-deoxyribosyl moiety.

3. The compound of claim 1 , wherein R 2 is hydrogen or halogen.

4. The compound of claim 3 , wherein halogen is fluoro.

5. The compound of claim 3 , wherein R 2 is hydrogen.

6. The compound of claim 1 , wherein:

R 2 is hydrogen or fluoro; and

the wavy line indicates a bond to the ribosyl, the 2′-deoxyribosyl, or the 2′, 3′-dideoxyribosyl moiety.

7. The compound of claim 6 , wherein R 2 is hydrogen.

8. The compound of claim 7 , wherein the wavy line indicates a bond to the ribosyl or the 2′-deoxyribosyl moiety.

9. The compound of claim 8 , having the structure:

10. The compound of claim 8 , having the structure:

11. The compound of claim 1 , wherein:

R 2 is hydrogen or halogen;

the wavy line indicates a bond to the ribosyl or the 2′-deoxyribosyl moiety; and

wherein the 5′-hydroxy group of the ribosyl or the 2′-deoxyribosyl moiety is bonded to a mono-phosphate, a diphosphate, or a triphosphate group.

12. The compound of claim 11 , wherein the 5′-hydroxy group of the ribosyl or 2′-deoxyribosyl moiety is bonded to the triphosphate group.

13. The compound of claim 1 , wherein

R 2 is hydrogen;

the wavy line indicates a bond to the ribosyl or the 2′-deoxyribosyl moiety; and

wherein the 5′-hydroxy group of the ribosyl or the 2′-deoxyribosyl moiety is bonded to the triphosphate group.

14. The compound of claim 1 , wherein the wavy line indicates a bond to the ribosyl moiety and wherein the compound is incorporated into an RNA oligonucleotide chain.

15. The compound of claim 14 , wherein R 2 is hydrogen.

16. The compound of claim 1 , wherein the wavy line indicates a bond to the 2′-deoxyribosyl moiety and wherein the compound is incorporated into an DNA oligonucleotide chain.

17. The compound of claim 16 , wherein R 2 is hydrogen.

18. A compound having the structure:

19. A compound having the structure:

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE THIRD INVENTOR'S LAST NAME PREVIOUSLY RECORDED AT REEL: 050269 FRAME: 0279. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jan 4, 2023
From: ROMESBERG, FLOYD E.; MALYSHEV, DENIS A.; LI, LINGJUN; LAVERGNE, THOMAS; LI, ZHENGTAO
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 062291/0579 →
CONFIRMATORY LICENSE Recorded Dec 22, 2017
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044950/0135 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2016
From: ROMESBERG, FLOYD E.; MALYSHEV, DENIS A.; LI, LINGJUN; LAVERGNE, THOMAS; LI, ZHENGTAO
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 040258/0961 →
Continuity (2)
Provisional Application 61863649 · Aug 8, 2013
Related Publication 20160168187A1 · Jun 16, 2016
Cited By (4)
US 12,281,137 US 12,319,944 US 12,497,642 US 12,655,436